贝伐单抗联合PC化疗方案治疗复发性卵巢癌的疗效研究  

Therapeutic effects of bevacizumab combined with paclitaxel-carboplatin chemotherapy on patients with recurrent ovarian cancer

作　　者：陈甦[1] 金松[1] 郑小妹[1] 

机构地区：[1]海南医学院附属医院妇产科,海口570102

出　　处：《西南国防医药》2016年第2期154-157,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的探索贝伐单抗（BEV）联合紫杉醇、卡铂（PC方案）治疗复发性卵巢癌的疗效和安全性。方法将78例一线化疗后在3~6个月内复发的卵巢癌患者随机分为3组,每组26例,3 w为1个治疗周期。PC组于每周期第1、8 d静脉滴注紫杉醇175 mg/m2,第1 d静脉滴注卡铂400 mg/m2;BEV组于每周期第1 d给予BEV 15 mg/kg;联合组在PC组化疗方案的基础上,于每周期第1 d化疗结束1 h后静脉滴注BEV 15 mg/kg。每例患者至少接受3个周期的治疗,比较3组在临床缓解率（RR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良反应方面的差异。结果 PC组RR为34.62%,DCR为69.23%,中位PFS和OS分别为5.81、13.27个月;BEV组RR为38.46%,DCR为76.92%,中位PFS和OS分别为6.50、14.69个月;联合组RR为69.23%,DCR为96.15%,中位PFS和OS分别为8.08、16.65个月。联合组在RR、DCR、中位PFS和中位OS上均高于PC组和BEV组（P〈0.05）,而PC组与BEV组之间则均无显著性差异（P〉0.05）;3组间的毒副反应无显著性差异（P〉0.05）。结论 BEV联合PC方案治疗复发性卵巢癌,可较好地缓解患者病情,改善患者生存时间,且未明显增加毒副反应。Objective To explore the therapeutic effects of bevacizumab （BEV） combined with paclitaxel-carboplatin （PC） chemotherapy on patients with recurrent ovarian cancer and the safety. Methods Seventy eight patients with ovarian cancer recurrent within 3 to 6 months after the first-line treatment scheme of chemotherapy were randomly and averagely divided into 3 groups. Three weeks was a treatment cycle. PC group was given intravenous drip with 175 mg/m2 paclitaxel on day 1 and 8 of every treatment cycle and 400 mg/m2 carboplatin on day l. BEV group was given 15 mg/kg BEV on day 1 of every treatment cycle. Combination group was given intravenous drip with 15 mg/kg BEV additionally 1 hour after the chemotherapy regimen on day 1 of every cycle based on same chemotherapy as PC group. Each patient received at least 3 cycles of treatment. Comparison was made in the clinical response rate （RR）, disease control rate （DCR）, progression-free survival （PFS）, overall survival （OS）, and adverse reactions among the three groups. Results In the PC group, the RR, DCR, and median PFS and OS were 34.62%, 69.23%, and 5.81 and 13.27 months, respectively. In the BEV group, the RR, DCR, and the median PFS and OS were 38.46%, 76.92%, and 6.50 and 14.69 months, respectively. In the combination group, the RR, DCR, and the median PFS and OS were 69.23%, 96.15%, and 8.08 and 16.65 months, respectively. The indexes above in the combination group were significantly higher than those in the PC and the BEV group （P 〈 0.05）, while the difference between the latter two groups was no significant （P 〉 0.05）. There were no significant differences in the toxic and adverse reactions among the three groups （P 〉 0.05）. Coaelusion The treatment with BEV combined with PC regimen on recurrent ovarian cancer can alleviate the patient＇s condition and improve their survival and do not increase adverse reactions obviously.

关 键 词：贝伐单抗 紫杉醇 卡铂 复发性卵巢癌 疗效 

分 类 号：R737.31[医药卫生—肿瘤]